Home » Newsletters » BioWorld Science

BioWorld Science

July 10, 2001

View Archived Issues

Licensing opportunity from NIH: mutations applicable for development of dengue vaccines

DPC-602 exerts antithrombotic effects in animals at doses not causing bleeding

Direct-acting factor Xa inhibitor PD-198961 shows promise for both arterial and venous thrombosis

Factor Xa-selective anticoagulant DPC-423 has oral bioavailability and antithrombotic activity

CI-1031 may have a more favorable therapeutic index than enoxaparin

Prolonged inhibition of factor Xa with SanOrg-34006 provides high patency rate after thrombolysis

Acquisition of Aurora by Vertex cleared by FTC

Agouron returns Remune rights to Immune Response

Mixed thrombin, factor Xa and platelet aggregation inhibition provided by BIBR-830ZW

Metabolex begins phase I trials of MBX-102

FDA grants orphan drug status to Avigen's Coagulin-B

Ixense/Uprima launched in Germany, France and Spain for treatment of ED

ISTH news: promising new factor VIIa inhibitor synthesized at Ajinomoto

Role for olanzapine in Alzheimer's disease patients with BPSD

Xenova receives FDA approval to resume clinical trials with anticocaine addiction vaccine

Pharmacological profile of dual TxA2 antagonist and Tx synthase inhibitor discussed at ISTH

NCX-4016 has distinct pharmacological properties from acetylsalicylic acid

First nonpeptide protease inhibitor effective in patients failing PI-containing regimens

Alteon begins SAPPHIRE trial of ALT-711 for treatment of isolated systolic hypertension

Tricyclic PCOs reported by Abbott, particularly useful in bladder disorders

Lilly patents new thrombin inhibitors with improved PK profile

Imidazole-based PDE and TNF-alpha production inhibitors identified at Merck

Potential treatments for angiogenic disorders claimed by GSK company

New thiazolidinediones under evaluation by Vita-Invest

Preparation, activity and use of new series of GlyT-1 inhibitors

Boehringer Ingelheim discovers new tryptase inhibitors

Nociceptin receptor ligands discovered at Novo Nordisk to be useful against hot flashes

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
In the clinic for April 21, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Agenus, Astrazeneca, Briacell, Clearmind, Greenwich, Intodna,...